نتایج جستجو برای: cyp2c9

تعداد نتایج: 1925  

Journal: :Hippokratia 2014
E Yildirim K Erol A Birdane

BACKGROUND To determine the contribution of cytochrome P4502C9 (CYP2C9), vitamin K epoxide reductase (VKORC1) and factor VII genotypes, age, body mass index (BMI), international normalized ratio (INR) and other individual patient characteristics on warfarin dose requirements in an adult Turkish population. METHODS Blood samples were collected from 101 Turkish patients. Genetic analyses for CY...

2014
Mengchun Chen Youting Zhang Peipei Pan Li Wang Yunyun Zhan Hui Jin Mengmin Xia Xianqin Wang Dapeng Dai Jianping Cai Guoxin Hu

Cytochrome P450 (P450) 2C9 is an important member of the P450 enzyme superfamily, with 58 CYP2C9 allelic variants previously reported. Genetic polymorphisms of CYP2C9 significantly influence the efficacy and safety of some drugs, which might cause adverse effects and therapeutic failure. The aim of this study was to assess the catalytic activities of 38 human CYP2C9 alleles, including 24 novel ...

Journal: :Molecular pharmacology 2012
Nico Scheer Yury Kapelyukh Lynsey Chatham Anja Rode Sandra Buechel C Roland Wolf

Compared with rodents and many other animal species, the human cytochrome P450 (P450) Cyp2c gene cluster varies significantly in the multiplicity of functional genes and in the substrate specificity of its enzymes. As a consequence, the use of wild-type animal models to predict the role of human CYP2C enzymes in drug metabolism and drug-drug interactions is limited. Within the human CYP2C clust...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2007
Masashi Nagata Muneaki Hidaka Hiroshi Sekiya Yohei Kawano Keishi Yamasaki Manabu Okumura Kazuhiko Arimori

In this study, we investigated whether pomegranate juice could inhibit CYP2C9 activity. The ability of pomegranate juice to inhibit the diclofenac 4'-hydroxylase activity of human CYP2C9 was examined using human liver microsomes. Pomegranate juice was shown to be a potent inhibitor of human CYP2C9. The addition of 25 microl (5% v/v) of pomegranate juice resulted in almost complete inhibition of...

Journal: :The Journal of pharmacology and experimental therapeutics 2003
Ann-Charlotte Egnell Cecilia Eriksson Nan Albertson Brian Houston Scott Boyer

Positive cooperativity (auto- and heteroactivation) of drug oxidation, a potential cause of drug interactions, is well established in vitro for cytochrome P450 (P450) 3A4 but to a much lesser extent for other drug-metabolizing P450 isoforms. Using a high throughput fluorescent-based CYP2C9 effector assay, we identified >30 heteroactivators from a set of 1504 structurally diverse compounds. Seve...

Journal: :Croatian medical journal 2003
Nada Bozina Paula Granić Zdenka Lalić Inja Tramisak Mila Lovrić Ana Stavljenić-Rukavina

AIM To determine the prevalence of most common mutations of cytochrome P450 (CYP), ie, allelic variants of CYP2C9, CYP2C19, and CYP2D6, and to predict genotype frequency in the Croatian population. METHODS CYP genotype was determined in 200 non-related Croatian citizens. DNA isolated from blood samples was used for the analysis of the most common allelic variants of CYP2C9, CYP2C19, and CYP2D...

Journal: :Thrombosis and haemostasis 2008
Tom Schalekamp Anke-Hilse Maitland-van der Zee Anthonius de Boer

Thromb Haemost 2008; 100: 175–176 More than 60 years after its successful introduction for the prevention of thromboembolic events, the coumarin anticoagulant warfarin is still one of the most frequently prescribed cardiovascular drugs. The recently conducted Active W study once again established its therapeutic superiority over even a combination of antiplatelet drugs for the prevention of str...

Journal: :Thrombosis Journal 2008
Kari Bente Foss Haug Mohammad N Sharikabad Marianne K Kringen Sigrid Narum Stine T Sjaatil Per Wiik Johansen Peter Kierulf Ingebjørg Seljeflot Harald Arnesen Odd Brørs

BACKGROUND Warfarin treatment has a narrow therapeutic range, requiring meticulous monitoring and dosage titration. Individual dosage requirement has recently partly been explained by genetic variation of the warfarin metabolizing enzyme CYP2C9 and the Vitamin K-activating enzyme VKORC1. In the WARIS-II study, comparing three different antithrombotic regimens after myocardial infarction, warfar...

2005
A. David Rodrigues

The market withdrawals of rofecoxib (Vioxx) and valdecoxib (Bextra) have focused considerable attention on the side effect profiles of cyclooxygenase (COX) inhibitors. As a result, attempts will be made to identify risk factors in the hope that physicians might be able to ensure patient safety. At first glance, CYP2C9 genotype might be considered a risk factor because many COX inhibitors are CY...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید